Objectives: Long-term results of radiotherapy in locally advanced prostate cancer are poor due to local and distant failures. Since prostate cancer is hormone dependent, tumor androgen deprivation may enhance tumor eradication. Methods: Three randomized phase III trials, RTOG and EORTC are reported: they assess androgen suppression by using a luteinizing hormone-releasing hormone analogue (LH-RHa) with or without androgen blockade before and during, or during and after external irradiation. Results: A gain in disease-free, local relapse-free and metastasis-free survival has been obtained (p < 0.001). Only the EORTC 22863 trial has reported a significant improvement in overall survival (p = 0.001) with an LH-RHa started the first day of radiotherapy and administered every 4 weeks over 3 years. In the RTOG 85-10 trial, and LH-RHa, initiated in the last week of radiation therapy and continued until relapse, increased overall survival only in patients with poorly differentiated tumor with a Gleason score of 8–10 (p = 0.03). Conclusion: Androgen suppression prior to and during radiation improves disease-free survival; adjuvant hormonal therapy with an LH-RHa during and after radiation improves overall survival.

Keywords:
Prostate cancer, Radiotherapy, Adjuvant hormonal treatment
1.
Bolla M, Bartelink H, Gibbons R, Gospodarowicz M, Hanks G, Kakizoe T, Meyoff H, Preziozo D, Senge T, Schaerer R: Treatment of regional disease; in Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds): Proceedings of the First International Consultation on Prostate Cancer; 1996 June 20–22, Monaco. Scientific Communication International Ltd, 1997, pp 259–266.
2.
Bolla M, van Poppel H: Prostate cancer: An insight into screening and local treatment (letter to the editor). Eur J Cancer 1996;32A:1434–1435.
3.
Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988;7:47–60.
4.
Hanks GE, Corn BW, Lee WR, Hunt M, Hanlon A, Schultheiss TE: External beam irradiation of cancer prostate: Conformal treatment techniques and outcomes for the 1990s. Cancer 1995;75:1972–1977.
5.
Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr: The effects of local and regional treatments of the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7–16.
6.
Schröder FH: What is new in endocrine therapy of prostatic cancer? in Newling DWW, Jones WG (eds): EORTC Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer. New York, Wiley-Liss, 1990, pp 45–52.
7.
Holtzman M, Carlton CE, Scardino PT: The frequency and morbidity of local recurrence after definitive radiotherapy for stage T3 prostate cancer. J Urol 1991;146:1578–1582.
8.
Van der Werf-Messing B, Sourek-Zikova V, Blouk DI: Localized advanced carcinoma of the prostate: Radiation therapy versus hormonal therapy. Int J Radiat Oncol Biol Phys 1976;1:1043–1048.
9.
Neglia WJ, Husson DH, Johnson DE: Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977;2:873–882.
10.
Taylor WJ, Richardson RG, Hafermann MD: Radiation therapy for localized prostate cancer. Cancer 1979;43:1123–1127.
11.
Fellows GJ, Clark PB, Beynon LL, Boreham J, Keen C, Parkinson MC, Peto R, Webb JN: Treatment of advanced localized prostatic cancer by orchiectomy, radiotherapy, or combined treatment: A Medical Research Council Study. Br J Urol 1992;70:304–309.
12.
Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616–623.
13.
Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 1997;15:1013–1021.
14.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.